AbbVie Inc. (ABBV) Receives CRL from the FDA About the Biologics License Application for trenibotulinumtoxinE

AbbVie Inc. (NYSE:ABBV) is one of the best low volatility stocks to invest in right now. AbbVie Inc. (NYSE:ABBV) announced on April 23 that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration regarding the Biologics License Application for trenibotulinumtoxinE, which is a first-in-class botulinum neurotoxin serotype E with a rapid onset of effect and short duration.

Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally

Management clarified that the FDA requested additional information about manufacturing processes in the letter, and added that neither does the CRL identify safety or efficacy concerns for TrenibotE nor does it request additional clinical studies. The company expressed confidence in its ability to address the FDA’s comments promptly and aims to submit a thorough response in the coming months. AbbVie Inc. (NYSE:ABBV) also reported that regulatory reviews for TrenibotE in other countries are ongoing and progressing as expected.

It also reported that TrenibotE’s safety and efficacy are supported by data from over 2,100 patients treated with TrenibotE in the clinical program. This includes two pivotal Phase 3 clinical studies evaluating TrenibotE for the treatment of moderate to severe glabellar lines and a Phase 3 open-label safety study.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.